HomeCompareBAX vs GPN

BAX vs GPN: Dividend Comparison 2026

BAX yields 2.28% · GPN yields 1.51%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GPN wins by $9.8K in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
GPN
GPN
● Live price
1.51%
Share price
$66.30
Annual div
$1.00
5Y div CAGR
27.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$2,458.46
Full GPN calculator →

Portfolio growth — BAX vs GPN

📍 GPN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXGPN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + GPN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
GPN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
GPN
Annual income on $10K today (after 15% tax)
$128.21/yr
After 10yr DRIP, annual income (after tax)
$2,089.69/yr
At 15% tax rate, GPN beats the other by $2,080.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + GPN for your $10,000?

BAX: 50%GPN: 50%
100% GPN50/50100% BAX
Portfolio after 10yr
$25.6K
Annual income
$1,234.36/yr
Blended yield
4.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GPN right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
GPN
Analyst Ratings
37
Buy
21
Hold
4
Sell
Consensus: Buy
Price Target
$94.25
+42.2% upside vs current
Range: $80.00 — $109.00
Altman Z
0.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
GPN buys
0
No recent congressional trades found for BAX or GPN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXGPN
Forward yield2.28%1.51%
Annual dividend / share$0.36$1.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%27.6%
Portfolio after 10y$20.6K$30.5K
Annual income after 10y$10.26$2,458.46
Total dividends collected$602.00$9.1K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$19.75$94.25

Year-by-year: BAX vs GPN ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrGPN PortfolioGPN Income/yrGap
1← crossover$10,866$166.33$10,892$192.46$26.00GPN
2$11,750$123.31$11,905$249.99$155.00GPN
3$12,664$90.97$13,064$325.83$400.00GPN
4$13,617$66.89$14,405$426.40$788.00GPN
5$14,619$49.07$15,974$560.68$1.4KGPN
6$15,679$35.94$17,834$741.46$2.2KGPN
7$16,802$26.30$20,069$987.14$3.3KGPN
8$17,998$19.23$22,799$1,324.75$4.8KGPN
9$19,272$14.05$26,189$1,794.67$6.9KGPN
10$20,631$10.26$30,481$2,458.46$9.8KGPN

BAX vs GPN: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

GPNStock

Global Payments Inc. provides payment technology and software solutions for card, electronic, check, and digital-based payments in the Americas, Europe, and the Asia-Pacific. It operates through three segments: Merchant Solutions, Issuer Solutions, and Business and Consumer Solutions. The Merchant Solutions segment offers authorization services, settlement and funding services, customer support and help-desk functions, chargeback resolution, terminal rental, sales and deployment, payment security services, consolidated billing and statements, and on-line reporting services. This segment also provides an array of enterprise software solutions that streamline business operations of its customers in various vertical markets; and value-added services, such as point-of-sale solutions, and analytic and engagement tools, as well as payroll and human capital management services. The Issuer Solutions segment offers solutions that enable financial institutions and retailers to manage their card portfolios through a platform; and commercial payments and ePayables solutions for businesses and governments. The Business and Consumer Solutions segment provides general-purpose reloadable prepaid debit and payroll cards, demand deposit accounts, and other financial service solutions to the underbanked and other consumers, and businesses under the Netspend brand. It markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, and independent sales organizations. The company was founded in 1967 and is headquartered in Atlanta, Georgia.

Full GPN Calculator →
📬

Get this BAX vs GPN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.